drugset / Trial / NCT06404281
γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This study intends to combine the advantages of γδ T cells and PD-1 monoclonal antibody to conduct an exploratory clinical study on the safety and efficacy of PD-1 antibody armored γδ T cells (γδ T-PD-1 Ab cells) in the treatment of advanced solid tumors.
Timeline
- Start
- 2024-08-01
- Primary completion
- 2026-01-01
- Completion
- 2026-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | γδ T-PD-1 Ab cells | Cell therapy | 3e+07 cells/kg | Other |
| Subject | γδ T-PD-1 Ab cells | Cell therapy | 1e+08 cells/kg | Other |
| Subject | γδ T-PD-1 Ab cells | Cell therapy | 3e+08 cells/kg | Other |